• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by TELA Bio Inc.

    8/11/25 5:14:16 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email
    S-8 1 tm2522741d1_s8.htm FORM S-8

     

    As filed with the United States Securities and Exchange Commission on August 11, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    TELA BIO, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware    45-5320061
    (State or other jurisdiction of incorporation or
    organization)
      (I.R.S. Employer Identification No.)

     

    1 Great Valley Parkway, Suite 24
     Malvern, Pennsylvania
      19355
    (Address of Principal Executive Offices)   (Zip Code)

     

    TELA BIO, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

    Antony Koblish
    Chief Executive Officer
    TELA Bio, Inc.
    1 Great Valley Parkway, Suite 24

    Malvern, Pennsylvania 19355

    (Name and address of agent for service)

     

    (484) 320-2930
    (Telephone number, including area code, of agent for service)

     

    Copies to:

    Rachael M. Bushey, Esq.
    Justin S. Platt, Esq.
    Goodwin Procter LLP

    3025 John F Kennedy Blvd
    Philadelphia, PA 19104
    (445) 207-7805

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    On April 3, 2025, the Board of Directors of TELA Bio, Inc. (the “Company”) adopted, subject to approval by the stockholders, an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan (the “Equity Plan”) (such amendment, the “Amendment” and the Equity Plan, after giving effect to the Amendment, the “Amended Equity Plan”), which the stockholders of the Company approved at the Company’s 2025 Annual Meeting of Stockholders held on May 28, 2025. The Amendment increased the number of shares of common stock, par value $0.001 per share, of the Company (“Common Stock”), authorized for issuance thereunder by 3,500,000 shares of Common Stock (the “Additional Shares”). This Registration Statement on Form S-8 (the “Registration Statement”) is being filed solely for the purpose of registering the Additional Shares for issuance under the Amended Equity Plan.

     

    Such Additional Shares are of the same class of securities as the shares of Common Stock issuable under the Equity Plan for which the currently effective Registration Statements on Form S-8 (File Nos. 333-235241 and 333-245707) filed with the Securities and Exchange Commission (the “Commission”) on November 25, 2019 and August 8, 2020, respectively (the “Prior Registration Statements”), were filed. Upon the effectiveness of this Registration Statement, an aggregate of 7,432,620 shares of Common Stock will be registered for issuance from time to time under the Amended Equity Plan, inclusive of the Additional Shares. Pursuant to General Instruction E of Form S-8 regarding registration of Additional Securities, the contents of the Prior Registration Statements are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Prior Registration Statement are presented herein.

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Registrant with the Commission are incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

     

    (a)            The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 21, 2025 (the “2024 10-K”);

     

    (b)            The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the Commission on May 8, 2025 and August 11, 2025;

     

    (b)           The Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 17, 2025, to the extent incorporated by reference into the 2024 10-K.

     

    (c)           The Registrant’s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed with the Commission on March 31, 2025, May 30, 2025 and June 2, 2025.

     

    (d)            The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on November 7, 2019 (File No. 001-39130), together with any amendment thereto filed with the Commission for the purpose of updating such description; and

     

    (e)            All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

     

     

     

     

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.  

     

    The following documents are filed as exhibits to this Registration Statement:

     

    Exhibit
    Number
      Description of Exhibit
    3.1   Fourth Amended and Restated Certificate of Incorporation of TELA Bio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-39130) filed on November 19, 2019).
    3.2   Certificate of Amendment to TELA Bio, Inc.’s Fourth Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-39130) filed on August 11, 2025).
    3.3   Third Amended and Restated Bylaws of TELA Bio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-39130) filed on November 13, 2023).
    4.1   Form of Certificate of Common Stock (incorporated herein by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1 (File No. 333-234217) filed on October 29, 2019).
    5.1*   Opinion of Goodwin Procter LLP as to the legality of the securities being registered.
    23.1*   Consent of KPMG LLP, independent registered public accounting firm for TELA Bio, Inc.
    23.2*   Consent of Goodwin Procter LLP (contained in Exhibit 5.1).
    24.1*   Power of Attorney (included on the signature page of the Registration Statement).
    99.1#   TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan (incorporated by reference to exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 8, 2020).
    99.2*   Amendment No. 1 to TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan.
    99.3#   Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Stock Option Grant Notice and Stock Option Agreement (incorporated by reference to exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed on May 11, 2022).
    99.4#   Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (time-based vesting) (incorporated by reference to exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q, filed on May 11, 2022).
    99.5#   Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (performance-based vesting) (incorporated by reference to exhibit 10.13 to the Company’s Annual Report on Form 10-K, filed on March 23, 2023).
    107*   Filing Fee Table.

     

    * Filed herewith
    # Denotes management contract or compensatory plan or arrangement

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of Malvern, Commonwealth of Pennsylvania, on August 11, 2025.

     

    TELA BIO, INC.  
         
    By: /s/ Antony Koblish  
      Antony Koblish  
      Chief Executive Officer and Director  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Antony Koblish and Roberto Cuca as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature    Title    Date 
             
    /s/ Antony Koblish   Chief Executive Officer and Director   August 11, 2025
    Antony Koblish   (Principal Executive Officer)    
             
    /s/ Roberto Cuca   Chief Operating Officer and Chief Financial Officer   August 11, 2025
    Roberto Cuca   (Principal Financial Officer)    
             
    /s/ Megan Smeykal   Chief Accounting Officer and Controller   August 11, 2025
    Megan Smeykal   (Principal Accounting Officer)    
             
    /s/ Doug Evans   Chairman, Board of Directors   August 11, 2025
    Doug Evans        
             
    /s/ Kurt Azarbazin   Director   August 11, 2025
    Kurt Azarbazin        
             
    /s/ Vince Burgess   Director   August 11, 2025
    Vince Burgess        
             
    /s/ Lisa Colleran   Director   August 11, 2025
    Lisa Colleran        
             
    /s/ Federica O’Brien   Director   August 11, 2025
    Federica O’Brien        

     

     

     

    Get the next $TELA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TELA Bio downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

    3/21/25 8:05:03 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on TELA Bio with a new price target

    Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

    5/31/22 9:13:36 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Firestone Gregory A. covered exercise/tax liability with 1,093 shares, decreasing direct ownership by 1% to 106,790 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    8/5/25 4:08:04 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    President Blizard Jeffrey was granted 104,800 shares, increasing direct ownership by 732% to 119,125 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    6/2/25 4:59:08 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Director Evans Douglas G was granted 7,950 shares, increasing direct ownership by 76% to 18,470 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    5/30/25 4:18:35 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TELA Bio Reports Second Quarter 2025 Financial Results

    MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the second quarter, resulting in year-over-year revenue increase for each product of approximately 12% and 53%, respectively;Appointed Jeffrey Bliz

    8/11/25 4:03:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or

    8/8/25 5:00:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference

    MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA's management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prior

    7/23/25 4:03:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:26:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Talmo Paul bought $50,000 worth of shares (22,222 units at $2.25), increasing direct ownership by 32% to 91,082 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:25:59 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Koblish Antony bought $199,998 worth of shares (88,888 units at $2.25), increasing direct ownership by 24% to 458,897 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:25:31 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

    SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    8/14/25 3:08:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by TELA Bio Inc.

    S-8 - TELA Bio, Inc. (0001561921) (Filer)

    8/11/25 5:14:16 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by TELA Bio Inc.

    10-Q - TELA Bio, Inc. (0001561921) (Filer)

    8/11/25 4:16:14 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Leadership Updates

    Live Leadership Updates

    View All

    TELA Bio Appoints Jeffrey Blizard as President

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

    6/2/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Appoints Jeffrey Blizard to its Board of Directors

    MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader

    6/4/24 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Appoints Greg Firestone as Chief Commercial Officer

    MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group

    5/20/24 4:03:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    11/14/24 1:06:57 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by TELA Bio Inc.

    SC 13G - TELA Bio, Inc. (0001561921) (Subject)

    10/29/24 5:12:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    10/28/24 4:06:51 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Financials

    Live finance-specific insights

    View All

    TELA Bio Reports Second Quarter 2025 Financial Results

    MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the second quarter, resulting in year-over-year revenue increase for each product of approximately 12% and 53%, respectively;Appointed Jeffrey Bliz

    8/11/25 4:03:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio to Announce Second Quarter 2025 Financial Results

    MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before

    7/21/25 4:03:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Reports First Quarter 2025 Financial Results

    MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

    5/8/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care